The latest Phase III trial tested Ocular Therapeutix's intracanalicular depot as a treatment for ocular itching associated with chronic allergic conjunctivitis; but the study did not meet its primary endpoint of difference in mean scores in ocular itching between the treatment group and the placebo comparator group at three time points seven days following insertion.
Ocular Therapeutix's share price (NASDAQ) dropped 42.5% on June 6, closing down at $6.81 per share. The company started this...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)